Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Pharmacogenomics. 2008 Jul;9(7):947-68. doi: 10.2217/14622416.9.7.947.

Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.

Author information

1
University of Florida College of Medicine, Department of Pediatrics, Gainesville, FL 32607, USA. jsilver007@yahoo.com

Abstract

Adenosine deaminase deficiency fosters a rare, devastating pediatric immune deficiency with concomitant opportunistic infections, metabolic anomalies and multiple organ system pathology. The standard of care for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID) includes enzyme replacement therapy or bone marrow transplantation. Gene therapies for ADA-SCID over nearly two decades have exclusively involved retroviral vectors targeted to lymphocytes and hematopoetic progenitors. These groundbreaking gene therapies represent a revolution in clinical medicine, but come with several challenges, including the risk of insertional mutagenesis. An alternative gene therapy for ADA-SCID may utilize recombinant adeno-associated virus vectors in vivo, with numerous target tissues, to foster ectopic expression and secretion of adenosine deaminase. This review endeavors to describe ADA-SCID, the traditional treatments, previous retroviral gene therapies, and primarily, alternative recombinant adeno-associated virus-based strategies to remedy this potentially fatal genetic disease.

PMID:
18597656
DOI:
10.2217/14622416.9.7.947
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center